Table 1.
Demographic data of patients, primary headache characteristics and its associated symptoms in three treatment groups
| p-value | Sodium Valproate | Acupuncture | Botulinum toxin-A | ||
|---|---|---|---|---|---|
| 0.876 | 37.6±7.4 | 37.2±7.3 | 36.8±7.4 | Age | |
| 0.461 | 17(33%) | 21(42%) | 23(46%) | Male | Gender |
| 33(66%) | 29(58%) | 27(54%) | Female | ||
| 0.407 | 9.15±3.95 | 10.34±5.46 | 9.22±5.31 | Duration of migraine (year) | |
| 0.224 | 4.11±2.45 | 4.22±3.57 | 3.23±3.19 | Duration of drug use (year) | |
| 0.072 | 21.02±4.36 | 21.26±6.84 | 23.56±6.46 | Day/month headache | |
| 0.060 | 14.1±5.06 | 14.56±5.62 | 17.76±6.18 | Number of drug use/month | |
| 0.120 | 8.36±1.39 | 8.56±1.29 | 8.9±1.24 | Headache severity (VAS* score) | |
| 0.443 | 45% | 48% | 45% | Absence from work (% of patients) | |
| 0.378 | 31(62%) | 36(72%) | 37(74%) | Photophobia | |
| 0.699 | 27(54%) | 30(60%) | 31(62%) | Phonophobia | |
| 0.707 | 26(52%) | 27(54%) | 23(46%) | Osmophobia | |
| 0.809 | 32(64%) | 34(68%) | 35(70%) | Pulsating | |
| 0.434 | 38(76%) | 41(82%) | 43(86%) | Nausea &Vomiting | |
*
Visual Analog Scale